Surgical Management of MEN-1 and -2: State of the Art

Surgical Clinics of North America

Volumn 89, Issue 5, 2009, Pages 1047-1068

  Åkerström, Göran ^a   Stålberg, Peter ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Genetic diagnosis; Multiple endocrine neoplasia type 1; Multiple endocrine neoplasia type 2; Surgical treatment; Surveillance

Indexed keywords

METHIONINE; PROTEIN RET; PROTON PUMP INHIBITOR;

DNA DETERMINATION; DUODENUM TUMOR; ENDOCRINE SURGERY; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; GLUCAGONOMA; HETEROZYGOTE; HUMAN; HYPERGASTRINEMIA; HYPOPHYSIS TUMOR; INSULINOMA; LABORATORY TEST; LYMPH NODE DISSECTION; MULTIPLE ENDOCRINE NEOPLASIA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; MUTATIONAL ANALYSIS; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PARATHYROID TUMOR; PARATHYROIDECTOMY; PHEOCHROMOCYTOMA; POSTOPERATIVE CARE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REOPERATION; REVIEW; RISK ASSESSMENT; SURGICAL APPROACH; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TREATMENT PLANNING; VIPOMA; ZOLLINGER ELLISON SYNDROME;

ADRENAL GLAND NEOPLASMS; CARCINOMA, MEDULLARY; ENDOCRINE SURGICAL PROCEDURES; GENETIC TESTING; GENOTYPE; HUMANS; HYPERPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PARATHYROIDECTOMY; PHEOCHROMOCYTOMA;

EID: 70349884316     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2009.06.016     Document Type: Review

References (111)

1. Chandrasekharappa S.C., Guru S.C., Manickam P., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276 (1997) 404-407
2. Lemos M.C., and Thakker R.V. Multiple endocrine neoplasia type 1 (MEN 1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 29 (2008) 22-32
3. Tham E., Grandell U., Lindgren E., et al. Clinical testing for mutations in the MEN 1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 92 (2007) 3389-3395
4. Skogseid B., Rastad J., and Åkerström G. Pancreatic endocrine tumors in multiple endocrine neoplasia type I. In: Doherty G.M., and Skogseid B. (Eds). Surgical endocrinology (2001), Lippincott Williams & Wilkins, Philadelphia 511-524
5. Skogseid B., Eriksson B., Lundquist G., et al. Multiple endocrine neoplasia type I: a 10-year prospective screening study in four kindreds. J Clin Endocrinol Metab 73 (1991) 281-287
6. Lairmore T.C., Piersall L.D., DeBenedetti M.K., et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN 1). Ann Surg 239 (2004) 637-645
7. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type1 and type2. J Clin Endocrinol Metab 86 (2001) 5658-5671
8. Uchino S., Noguchi S., Sato M., et al. Screening of the MEN 1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 60 (2000) 5553-5557
9. Langer P., Wild A., Hall A., et al. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumors. Br J Surg 90 (2003) 1599-1603
10. Burgess J.R., David R., Greenway T.M., et al. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 134 (1999) 1119-1123
11. Åkerström G., and Juhlin C. Surgical management of multiglandular parathyroid disease. In: Randolph G.W. (Ed). Surgery of the thyroid and parathyroid glands (2003), Saunders, Philadelphia 529-548
12. Norton J.A., Venzon D.J., Berna M.J., et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg 247 (2008) 501-510
13. Harach H.R., and Jasani B. Parathyroid hyperplasia in multiple endocrine neoplasia type 1: a pathological and immunohistochemical reappraisal. Histopathology 21 (1992) 513-519
14. Stålberg P, Carling T. Familial parathyroid tumors. In: Evidence Based Symposium on Hyperparathyroidism, World J Surg 2009 [epub ahead of print].
15. Åkerström G., Malmaeus J., and Bergström R. Surgical anatomy of human parathyroid glands. Surgery 95 (1984) 14-21
16. Hellman P., Skogseid B., Öberg K., et al. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery 124 (1998) 993-999
17. O'Riordain D.S., O'Brien T., Grant C.S., et al. Surgical management of primary hyperparathyroidism in multiple endocrine neoplasia types 1 and 2. Surgery 114 (1993) 1031-1037 [discussion: 1037-9]
18. Goudet P., Cougard P., Verges B., et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Neoplasies Endoccriniennes Multiples Study Group. World J Surg 25 (2001) 886-890
19. Elaraj D.M., Skarulis M.C., Libutti S.K., et al. Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery 134 (2003) 858-864 [discussion: 864-5]
20. Kraimps J.L., Denizot A., Carnaille B., et al. Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d'Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20 (1996) 808-812 [discussion: 812-3]
21. Wells S.A., Farndon J.R., Dale J.K., et al. Long-term evaluation of patients with primary parathyroid hyperplasia managed by total parathyroidectomy and heterotopic autotransplantation. Ann Surg 192 (1980) 451-458
22. Hubbard J.G.H., Sebag F., Maweja S., et al. Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1. Arch Surg 141 (2006) 235-239
23. Kivlen M., Bartlett D.L., Libutti S.K., et al. Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery 130 (2001) 991-998
24. Clerici T., Brandle M., Lange J., et al. Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease. World J Surg 28 (2004) 187-192
25. Thompson G.B., Grant C.S., Perrier N.D., et al. Reoperative parathyroid surgery in the era of sestamibi scanning and intraoperative parathyroid hormone monitoring. Arch Surg 134 (1999) 699-705
26. Udelsman R., and Donovan P.I. Remedial parathyroid surgery: changing trends in 130 consecutive cases. Ann Surg 244 (2006) 471-479
27. Hessman O., Stålberg P., Sundin A., et al. High success rate of parathyroid reoperation may be achieved with improved localization diagnosis. World J Surg 32 (2008) 774-781 [discussion: 782-3]
28. Rodgers S.E., Hunter G.J., Hamberg L.M., et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery 140 (2006) 932-940
29. Åkerström G., Hessman O., Hellman P., et al. Pancreatic tumours as part of the MEN-I syndrome. Best Pract Res Clin Gastroenterol 19 (2005) 819-830
30. Klöppel G., Willemer S., Stamm B., et al. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I: an immunocytochemical study of nine patients. Cancer 57 (1986) 1824-1832
31. Pipellers-Marichal M., Somers G., Willems E., et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type I and the Zollinger-Ellison syndrome. N Engl J Med 322 (1990) 723-727
32. Ekeblad S., Skogseid B., Dunder K., et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14 (2008) 7798-7803
33. Doherty G.M., Olson J.A., Frisella M.M., et al. Lethality of multiple endocrine neoplasia type I. World J Surg 22 (1998) 581-587
34. Dean P.G., van Heerden J.A., Farley D.R., et al. Are patients with multiple endocrine neoplasia type I prone to premature death?. World J Surg 24 (2000) 1437-1441
35. Lowney J., Frisella M.M., Lairmore T.C., et al. Islet cell tumor metastasis in multiple endocrine neoplasia type I: correlation with primary tumor size. Surgery 124 (1998) 1043-1049
36. Skogseid B., Öberg K., Eriksson B., et al. Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J Surg 20 (1996) 872-877
37. Åkerström G., Johansson H., and Grama G. Surgical treatment of endocrine pancreatic lesions in MEN-I. Acta Oncol 30 (1991) 541-545
38. Grama D., Skogseid B., Wilander E., et al. Pancreatic tumors in multiple endocrine neoplasia type I: clinical presentation and surgical treatment. World J Surg 16 (1992) 611-619
39. Skogseid B., Öberg K., and Åkerström G. Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization?. World J Surg 22 (1998) 673-678
40. Triponez F., Goudet P., Dosseh D., et al. Is surgery beneficial for MEN 1 patients with small (≤2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 30 (2006) 654-662
41. Triponez F., Dosseh D., Goudet P., et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 243 (2006) 265-272
42. Doherty G.M., and Thompson N.W. Multiple endocrine neoplasia type 1: duodenopancreatic tumours. J Intern Med 253 (2003) 590-598
43. Bartsch D.K., Fendrich V., Langer P., et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242 (2005) 757-766
44. Hellman P., Hennings J., Åkerström G., et al. Endoscopic ultrasound for evaluation of pancreatic tumors in multiple endocrine neoplasia type 1. Br J Surg 92 (2005) 1508-1512
45. O'Riordian D.S., O'Brian T., van Heerden J.A., et al. Surgical management of insulinoma associated with multiple endocrine neoplasia type 1. World J Surg 18 (1994) 488-494
46. Demeure M.J., Klonoff C.C., Karam J.H., et al. Insulinomas associated with multiple endocrine neoplasia type 1: the need for a different surgical approach. Surgery 110 (1991) 998-1005
47. Grant C.S. Insulinoma. Best Pract Res Clin Gastroenterol 19 (2005) 783-798
48. Kato M., Imamura M., Hosotani R., et al. Curative resection of microgastrinomas based on the intraoperative secretin test. World J Surg 24 (2000) 1425-1430
49. Levy-Bohbot N., Merie C., Goudet P., et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas. Gastroenterol Clin Biol 28 (2004) 1075-1081
50. Bartsch D., Langer P., Wild A., et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?. Surgery 128 (2000) 958-966
51. Hellman P., Ladjevardi S., Skogseid B., et al. Radiofrequency tissue ablation using coiled tip for liver metastases of endocrine tumors. World J Surg 26 (2002) 1052-1056
52. Thompson N.W., Vinik A.I., and Eckhauser F. Microgastrinomas of the duodenum: a cause of failed operations for the Zollinger-Ellison syndrome. Ann Surg 168 (1989) 396-404
53. Thompson N.W. Current concept in the surgical management of multiple endocrine neoplasia type 1 pancreaticoduodenal disease: results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 243 (1998) 495-500
54. Norton J.A., Fraker D.L., Alexander H.R., et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 341 (1999) 635-644
55. Norton J., and Jensen R.T. Role of surgery in Zollinger-Ellison syndrome. J Am Coll Surg 205 Suppl 4 (2007) S34-S37
56. Åkerström G., Hellman P., and Stålberg P. Carcinoid: presentation and diagnosis, surgical management. In: Hubbard J.G.H., Inabnet W.B., and Lo C.-Y. (Eds). Endocrine surgery (Springer Specialist Surgery Series) (2008), Springer-Verlag, London Chapter 44
57. Modlin I.M., and Lawton G.P. Duodenal gastrinoma: the solution to the pancreatic paradox. J Clin Gastroenterol 19 (1994) 184-188
58. Hausman Jr. M.S., Thompson N.W., Gauger P.G., et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136 (2004) 1205-1211
59. Tonelli F., Fratini G., Falchetti A., et al. Surgery for gastroenteropancreatic tumors in multiple endocrine neoplasia type 1: review and personal experience. J Intern Med 257 (2005) 38-49
60. Imamura M., Komoto I., Doi R., et al. New pancreas-preserving total duodenectomy technique. World J Surg 29 (2005) 203-207
61. Richards M.L., Gauger P., Thompson N.W., et al. Regression of type II gastric carcinoids. World J Surg 28 (2004) 652-658
62. Norton J.A., Melcher M.L., Gibril F., et al. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery 136 (2004) 1267-1274
63. Tisell L.E., Ahlman H., Jansson S., et al. Total pancreatectomy in the MEN 1 syndrome. Br J Surg 75 (1988) 154-157
64. You Y.N., Thompson G.B., Young W.F., et al. Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery 142 (2007) 829-836
65. Kouvaraki M.A., Shapiro S.E., Cote G.J., et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 30 (2006) 643-653
66. Tonelli F., Fratini G., Nesi G., et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 244 (2006) 61-70
67. Wilson S.D., Krzywda E.A., Zhu Y-r, et al. The influence of surgery in MEN-1 syndrome: observations over 150 years. Surgery 144 (2008) 695-702
68. Norton J.A., and Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 240 (2004) 757-773
69. Lairmore T.C., Chen V.Y., DeBenedetti M.K., et al. Duodenopancreatic resections in patients with multiple endocrine neoplasia type I. Ann Surg 231 (2000) 909-918
70. Mulligan L.M., Eng C., Healey C.S., et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 6 (1994) 70-74
71. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET Mutation Consortium Analysis. JAMA 276 (1996) 1575-1579
72. Kouvaraki M.A., Shapiro S.E., Perrier N.D., et al. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15 (2005) 531-544
73. Raue F., and Frank-Raue K. Multiple endocrine neoplasia type 2: 2007 update. Horm Res 68 Suppl 5 (2007) 101-104
74. Callender G.G., Rich T.A., and Perrier N.D. Multiple endocrine neoplasia syndromes. Surg Clin North Am 88 (2008) 863-895
75. Schimke R.N., Hartmann W.H., Prout T.E., et al. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in the differentiation of chromaffin tissue. N Engl J Med 279 (1968) 1-7
76. Wray C.J., Rich T.A., Waguespack S.G., et al. Failure to recognize multiple endocrine neoplasia 2B: more common than we think?. Ann Surg Oncol 15 (2008) 293-301
77. Farndon J.R., Leight G.S., Dilley W.G., et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 73 (1986) 278-281
78. Grant C.S. Medullary thyroid carcinoma and associated multiple endocrine neoplasia type 2. In: Hay I.D., and Wass J.A.H. (Eds). Clinical endocrine oncology. 2nd edition (2008), Blackwell Publishing, Singapore 515-522
79. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
80. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 (1993) 851-856
81. Mulligan L.M., Marsh D.J., Robinson B.G., et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 238 (1995) 343-346
82. Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 335 (1996) 943-951
83. Machens A., and Dralle H. DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer. Surgery 139 (2006) 279-282
84. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
85. Eng C., Smith D.P., Mulligan L.M., et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 3 (1994) 237-241
86. Zedenius J., Larsson C., Bergholm U., et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 80 (1995) 3088-3090
87. Alemi M., Lucas S.D., Sallstrom J.F., et al. A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma. Oncogene 14 (1997) 2041-2045
88. Elisei R., Romei C., Cosci B., et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92 (2007) 4725-4729
89. Yip L., Cote G.L., Shapiro S.E., et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg 138 (2003) 409-416
90. Nilsson O., Tisell L.E., Jansson S., et al. Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. JAMA 281 (1999) 1587-1588
91. Learoyd D.L., Gosnell J., Elston M.S., et al. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations. Clin Endocrinol (Oxf) 63 (2005) 636-641
92. Vasen H.F., van der Feltz M., Raue F., et al. The natural course of multiple endocrine neoplasia type 2b. Arch Intern Med 152 (1992) 1250-1252
93. Smith D.P., Houghton C., and Ponder B.A. Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15 (1995) 1213-1217
94. Gimm O., Ukkat J., Niederle B.E., et al. Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2A-related RET mutations not affecting codon 634. World J Surg 28 (2004) 1312-1316
95. Learoyd D.L., and Robinson B.G. Do all patients with RET mutations associated with multiple endocrine neoplasia type 2 require surgery?. Nat Clin Pract Endocrinol Metab 1 (2005) 60-61
96. Machens A., and Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg 31 (2007) 957-968
97. Frohnauer M.K., and Decker R.A. Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated?. Surgery 128 (2000) 1052-1057 [discussion: 1057-8]
98. Webb T.A., Sheps S.G., and Carney J.A. Differences between sporadic pheochromocytoma and pheochromocytoma in multiple endocrine neoplasia, type 2. Am J Surg Pathol 4 (1980) 121-126
99. Yip L., Lee J.E., Shapiro S.E., et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198 (2004) 525-534 [discussion: 534-5]
100. Åkerström G., and Hellman P. Genetic syndromes associated with adrenal tumors. In: Linos D., and van Heerden J.A. (Eds). Adrenal surgery (2005), Springer, Heidelberg, Germany 251-254
101. Modigliani E., Vasen H.M., Raue K., et al. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. J Intern Med 238 (1995) 363-367
102. Casanova S., Rosenberg-Bourgin M., Farkas D., et al. Phaeochromocytoma in multiple endocrine neoplasia type 2A: survey of 100 cases. Clin Endocrinol 38 (1993) 531-537
103. Lairmore T.C., Ball D.W., Baylin S.B., et al. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 217 (1993) 595-603
104. Pomares F.J., Canas R., Rodriguez J.M., et al. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol 48 (1998) 195-200
105. Lee J.E., Curley S.A., Gagel R.F., et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120 (1996) 1064-1071
106. Inabnet W.B., Caragliano P., and Pertsemlidis D. Pheochromocytoma, inherited associations, bilaterality, and cortex preservation. Surgery 128 (2000) 1007-1012
107. Walz M.K., Peitgen K., Diesing D., et al. Partial versus total adrenalectomy by the posterior retroperitoneoscopic approach: early and long-term results of 325 consecutive procedures in primary adrenal neoplasia. World J Surg 28 (2004) 1323-1329
108. Asari R., Scheuba C., Kaczirek K., et al. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. Arch Surg 141 (2006) 1199-1205
109. Brauckhoff M., Gimm O., Brauckhoff K., et al. Repeated adrenocortical-sparing adrenalectomy for recurrent hereditary pheochromocytoma. Surg Today 34 (2004) 251-255
110. Raue F., Kraimps J.L., Dralle H., et al. Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238 (1995) 369-373
111. Snow K.J., and Boyd A.E. Management of individual tumor syndromes: medullary thyroid carcinoma and hyperparathyroidism. Endocrinol Metab Clin North Am 23 (1994) 157-166